Please login to the form below

Not currently logged in

Fresenius sells biotech business

Germany company's biotechnology arm picked up by Neopharm owners


German healthcare group Fresenius has sold its biotech business for an undisclosed amount to the owners of Neopharm, Israel's second-largest pharma company.

The deal gives the Fuhrer family control of both the monoclonal antibody malignant ascites treatment Removab and ATG-Fresenius S, an immunosuppressive for use in organ transplantation therapy.

David Fuhrer, chairman and CEO of Neopharm, said: "The acquisition represents a cornerstone in our strategic objective to transform Neopharm Group into a multinational fully-integrated bio-pharmaceutical company.

“Our objective is to establish Fresenius Biotech as an independent, rapidly-growing, innovative global player which is committed to bring hope to patients suffering from rare, life-threatening diseases.”
The deal follows Fresenius' December 2012 decision to focus on its four established business segments Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed.

The company said it expects these segments to provide “significant growth opportunities” and added that it expected its agreement with Neopharm to have a positive effect on Group earnings from July.

Ulf Mark Schneider, Fresenius CEO, said: "The divestiture underlines our strong commitment to focused growth in our four core business segments. We are delighted that our biotechnology business will be in the capable hands of Neopharm, a company with entrepreneurial vision and an outstanding track record in the healthcare field."

1st July 2013

From: Research, Sales



Featured jobs

Subscribe to our email news alerts


Add my company
GEM Marketing Ltd

GEM, a small but perfectly formed integrated marketing agency servicing the pharmaceutical industry....

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...